Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
A phase 1/2 trial of Pembrolizumab, Olaparib, Docetaxel in prostate cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) is a phase 1/2 interventional study registered as NCT02861573 by Merck Sharp & Dohme LLC, with 1200 participants planned, started 2016-11-17 and due to reach its primary completion in 2027-10-22. Interventions recorded: Pembrolizumab 200 mg, Olaparib 400 mg, Docetaxel 75 mg/m^2, Prednisone 5 mg, Enzalutamide 160 mg. Conditions listed: Metastatic Castration-Resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Shares Enzalutamide, Abiraterone acetate, Docetaxel, Prostate cancer.
- TrialThe Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Shares Enzalutamide, Abiraterone acetate, Docetaxel, Prostate cancer.
- TrialAn Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Canc
Shares Enzalutamide, Abiraterone acetate, Prostate cancer.
- TrialStudy on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
Shares Abiraterone acetate, Olaparib, Prostate cancer.
- TrialPlacebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-
Shares Olaparib, Merck & Co. (MSD), Pembrolizumab.
- TrialA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Shares Enzalutamide, Docetaxel, Merck & Co. (MSD), Prostate cancer.
- TrialPROpel
Shares Abiraterone acetate, Olaparib, Prostate cancer.
- TrialPembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Shares Lenvatinib, Merck & Co. (MSD), Pembrolizumab.